Clinical trial NCT04918108: Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Multicenter Cohort Study) III
Official title: Inflammatory Response and Anti-inflammatory Action for Aortopathy & Arteriopathy (5A-Plan): A Multicenter Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Aortic Dissection
Keywords: Aortic Dissection
Inflammatory Response
Lead sponsor: Nanjing Medical University
Sponsor class: OTHER
Collaborators: name: The First Affiliated Hospital with Nanjing Medical University
name: Beijing Anzhen Hospital
name: The Affiliated Hospital of Qingdao University
name: First Affiliated Hospital of Shantou University Medical College
name: The First Affiliated Hospital of Guangzhou Medical University
name: TEDA International Cardiovascular Hospital
name: Xiamen Cardiovascular Hospital
name: Shanghai East Hospital Tongji University
name: Tianjin Chest Hospital, Tianjin Medical University
name: Nanjing First Hospital, Nanjing Medical University
name: Xiangya Hospital of Central South University
name: The First Affiliated Hospital of Bengbu Medical University
First posted: 2021-06-08
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients underwent venipuncture during primary evaluation in the Emergency Department. Venous blood samples were immediately sent to the laboratory for analysis.

Brief summary: Anatomopathological classifications have been well identified in aortic dissection with important therapeutic implications. The authors evaluated the inflammatory response in patients with aortic dissection (AD) and assessed the presence of distinct inflammatory subphenotypes within this disease.


Eligibility criteria: Inclusion Criteria:

* acute type Aortic dissection;

Exclusion Criteria:

* Iatrogenic aortic dissection OR traumatic aortic dissection
* Patients with hematological diseases, infectious diseases, malignant tumors, immune system diseases, or severe liver diseases.
* Preoperative use of mechanical ventilation, blood transfusion, renal replacement therapy, extracorporeal membrane oxygenation, or intra-aortic balloon pump during the current admission.

Primary outcomes:
measure: 30-day mortality
timeFrame: 30 days after surgery
Secondary outcomes:
measure: ICU mortality
timeFrame: 7 days after surgery
Other outcomes:
Locations:
city: Nanjing
country: China
facility: The first affiliated hospital of nanjing medical university
state: Jiangsu
Study officials:
References:
citation: Liu H, Qian SC, Han L, Dong ZQ, Shao YF, Li HY, Zhang W, Zhang HJ. Laboratory signatures differentiate the tolerance to hypothermic circulatory arrest in acute type A aortic dissection surgery. Interact Cardiovasc Thorac Surg. 2022 Nov 8;35(6):ivac267. doi: 10.1093/icvts/ivac267.
citation: Liu H, Qian SC, Zhang YY, Wu Y, Hong L, Yang JN, Zhong JS, Wang YQ, Wu DK, Fan GL, Chen JQ, Zhang SQ, Peng XX, Shao YF, Li HY, Zhang HJ. A Novel Inflammation-Based Risk Score Predicts Mortality in Acute Type A Aortic Dissection Surgery: The Additive Anti-inflammatory Action for Aortopathy and Arteriopathy Score. Mayo Clin Proc Innov Qual Outcomes. 2022 Sep 25;6(6):497-510. doi: 10.1016/j.mayocpiqo.2022.08.005. eCollection 2022 Dec.
citation: Liu H, Qian SC, Shao YF, Li HY; Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (5A) Investigators Group. Anti-Inflammatory Effect of Ulinastatin on the Association Between Inflammatory Phenotypes in Acute Type A Aortic Dissection. J Inflamm Res. 2022 Jun 27;15:3709-3718. doi: 10.2147/JIR.S369703. eCollection 2022.